John B. Green Sells 12,500 Shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Stock

Share on StockTwits

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) CFO John B. Green sold 12,500 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $21.05, for a total transaction of $263,125.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

John B. Green also recently made the following trade(s):

  • On Thursday, November 14th, John B. Green sold 3,562 shares of Dicerna Pharmaceuticals stock. The stock was sold at an average price of $20.00, for a total transaction of $71,240.00.
  • On Thursday, October 31st, John B. Green sold 12,500 shares of Dicerna Pharmaceuticals stock. The stock was sold at an average price of $18.00, for a total transaction of $225,000.00.

DRNA opened at $23.09 on Friday. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -19.24 and a beta of 2.29. Dicerna Pharmaceuticals Inc has a 52-week low of $9.31 and a 52-week high of $24.10. The firm’s fifty day simple moving average is $16.86 and its two-hundred day simple moving average is $14.66.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.15). The company had revenue of $8.04 million for the quarter, compared to analysts’ expectations of $11.70 million. Dicerna Pharmaceuticals had a negative net margin of 541.24% and a negative return on equity of 58.92%. As a group, sell-side analysts expect that Dicerna Pharmaceuticals Inc will post -1.37 earnings per share for the current fiscal year.

DRNA has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th. ValuEngine raised shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, November 6th. Cowen reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Monday. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective (up from $22.00) on shares of Dicerna Pharmaceuticals in a report on Tuesday. Finally, Chardan Capital reaffirmed a “buy” rating and set a $18.00 price objective on shares of Dicerna Pharmaceuticals in a report on Tuesday, August 13th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $24.50.

Institutional investors and hedge funds have recently bought and sold shares of the business. Swiss National Bank lifted its holdings in Dicerna Pharmaceuticals by 9.5% during the second quarter. Swiss National Bank now owns 87,600 shares of the biopharmaceutical company’s stock valued at $1,380,000 after purchasing an additional 7,600 shares in the last quarter. Alberta Investment Management Corp acquired a new stake in shares of Dicerna Pharmaceuticals in the third quarter valued at about $784,000. Northern Trust Corp raised its position in shares of Dicerna Pharmaceuticals by 3.7% in the second quarter. Northern Trust Corp now owns 683,682 shares of the biopharmaceutical company’s stock valued at $10,768,000 after buying an additional 24,348 shares during the last quarter. Eagle Asset Management Inc. acquired a new stake in shares of Dicerna Pharmaceuticals in the third quarter valued at about $25,347,000. Finally, Quantamental Technologies LLC raised its position in shares of Dicerna Pharmaceuticals by 94.4% in the second quarter. Quantamental Technologies LLC now owns 3,500 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 1,700 shares during the last quarter. 87.24% of the stock is currently owned by institutional investors and hedge funds.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Featured Article: Diluted Earnings Per Share

Insider Buying and Selling by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

BidaskClub Upgrades Neurocrine Biosciences  to Strong-Buy
BidaskClub Upgrades Neurocrine Biosciences to Strong-Buy
Johnson Outdoors  Issues  Earnings Results, Beats Expectations By $0.60 EPS
Johnson Outdoors Issues Earnings Results, Beats Expectations By $0.60 EPS
Resources Connection  Stock Rating Upgraded by BidaskClub
Resources Connection Stock Rating Upgraded by BidaskClub
BidaskClub Upgrades Xenon Pharmaceuticals  to “Buy”
BidaskClub Upgrades Xenon Pharmaceuticals to “Buy”
Zacks Investment Research Downgrades Piedmont Lithium  to Sell
Zacks Investment Research Downgrades Piedmont Lithium to Sell
VIVO  Price Reaches $0.0004
VIVO Price Reaches $0.0004


 
© 2006-2019 Zolmax.